Targeting FGFR signaling in cancer

M Touat, E Ileana, S Postel-Vinay, F André… - Clinical cancer …, 2015 - AACR
The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary
conserved signaling cascade that regulates several basic biologic processes, including …

[HTML][HTML] Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

YK Chae, K Ranganath, PS Hammerman, C Vaklavas… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase
signaling pathway that has a fundamental role in many biologic processes including …

[HTML][HTML] A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma …

E Van Cutsem, YJ Bang, W Mansoor, RD Petty… - Annals of …, 2017 - Elsevier
ABSTRACT Background Approximately 5%–10% of gastric cancers have a fibroblast growth
factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine …

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

RC Coombes, PD Badman, JP Lozano-Kuehne… - Nature …, 2022 - nature.com
We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL;
NCT01791985) of AZD4547 (a potent and selective inhibitor of Fibroblast Growth Factor …

Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with …

PK Paik, R Shen, H Won, N Rekhtman, L Wang… - Cancer discovery, 2015 - AACR
Large-scale genomic characterization of squamous cell lung cancers (SQCLC) has revealed
several putative oncogenic drivers. There are, however, little data to suggest that these …

[HTML][HTML] Clinicopathologic features of advanced squamous NSCLC

MA Socinski, C Obasaju, D Gandara, FR Hirsch… - Journal of Thoracic …, 2016 - Elsevier
Lung cancer remains the leading cause of cancer-related death worldwide. NSCLC
accounts for more than 85% of all lung cancers, and the prognosis for advanced-stage …

[HTML][HTML] FGFR signaling as a target for lung cancer therapy

A Desai, AA Adjei - Journal of Thoracic Oncology, 2016 - Elsevier
Lung cancer is the leading cause of cancer-related death in developed countries. Recently,
molecular targeted therapies have shown promising results in the management of lung …

[HTML][HTML] A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

AW Tolcher, KP Papadopoulos, A Patnaik, K Wilson… - Annals of …, 2016 - Elsevier
ABSTRACT Background Fibroblast growth factors (FGFs) play important roles in multiple
cancers by supporting tumor growth and angiogenesis. FP-1039 (GSK3052230) is a FGF …

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study

SH Lim, JM Sun, YL Choi, HR Kim, S Ahn, JY Lee… - Cancer, 2016 - Wiley Online Library
BACKGROUND Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential
driving oncogene in squamous cell cancer (SCC) of the lung. The current phase 2 study …

[HTML][HTML] The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

G Middleton, LR Crack, S Popat, C Swanton… - Annals of …, 2015 - Elsevier
Background The management of NSCLC has been transformed by stratified medicine. The
National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally …